Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

Axitinib for preoperative downstaging of renal cell carcinoma with sarcomatoid differentiation and direct invasion of the duodenum and inferior vena cava: a case report.

Yuki H, Kamai T, Kubota K, Abe H, Nishihara D, Mizuno T, Masuda A, Betsunoh H, Yashi M, Fukabori Y, Yoshida K.

Onco Targets Ther. 2014 Feb 15;7:289-95. doi: 10.2147/OTT.S58089. eCollection 2014.

2.

Axitinib for the management of metastatic renal cell carcinoma.

Escudier B, Gore M.

Drugs R D. 2011;11(2):113-26. doi: 10.2165/11591240-000000000-00000. Review.

3.

Presurgical therapy with axitinib for advanced renal cell carcinoma: a case report.

Koie T, Ohyama C, Okamoto A, Yamamoto H, Imai A, Hatakeyama S, Yoneyama T, Hashimoto Y.

BMC Res Notes. 2013 Nov 24;6:484. doi: 10.1186/1756-0500-6-484.

4.

Axitinib safety in metastatic renal cell carcinoma: suggestions for daily clinical practice based on case studies.

Bracarda S, Castellano D, Procopio G, Sepúlveda JM, Sisani M, Verzoni E, Schmidinger M.

Expert Opin Drug Saf. 2014 Apr;13(4):497-510. doi: 10.1517/14740338.2014.888413. Review.

PMID:
24641566
5.

Preoperative metastatic status, level of thrombus and body mass index predict overall survival in patients undergoing nephrectomy and inferior vena cava thrombectomy.

Spiess PE, Kurian T, Lin HY, Rawal B, Kim T, Sexton WJ, Pow-Sang JM.

BJU Int. 2012 Dec;110(11 Pt B):E470-4. doi: 10.1111/j.1464-410X.2012.11155.x. Epub 2012 Apr 23.

6.

Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatment.

Grünwald V, Merseburger AS.

Onco Targets Ther. 2012;5:111-7. doi: 10.2147/OTT.S23273. Epub 2012 Jun 18.

7.

Axitinib in Metastatic Renal Cell Carcinoma.

Mittal K, Wood LS, Rini BI.

Biol Ther. 2012 Oct 16;2:5. eCollection 2012. Review.

8.

Evaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinoma.

Gunnarsson O, Pfanzelter NR, Cohen RB, Keefe SM.

Cancer Manag Res. 2015 Feb 11;7:65-73. doi: 10.2147/CMAR.S74202. eCollection 2015. Review.

9.

Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trial.

Ueda T, Uemura H, Tomita Y, Tsukamoto T, Kanayama H, Shinohara N, Tarazi J, Chen C, Kim S, Ozono S, Naito S, Akaza H.

Jpn J Clin Oncol. 2013 Jun;43(6):616-28. doi: 10.1093/jjco/hyt054. Epub 2013 Apr 28.

10.

Axitinib: a review in advanced renal cell carcinoma.

Keating GM.

Drugs. 2015 Nov;75(16):1903-13. doi: 10.1007/s40265-015-0483-x.

PMID:
26487541
11.

Surgical management of renal cell carcinoma with inferior vena cava tumor thrombus.

Kaplan S, Ekici S, Doğan R, Demircin M, Ozen H, Paşaoğlu I.

Am J Surg. 2002 Mar;183(3):292-9.

PMID:
11943130
12.

Tumor Thrombus of Renal Cell Carcinoma Extending Into the Inferior Vena Cava, Ovarian Vein, and Ureter Treated With Neoadjuvant Axitinib.

Komatsubara M, Yamazaki M, Fujisaki A, Kurokawa S, Morita T.

Urology. 2016 Jun 9. pii: S0090-4295(16)30268-0. doi: 10.1016/j.urology.2016.05.057. [Epub ahead of print]

PMID:
27292564
13.

Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials.

Coppin C, Kollmannsberger C, Le L, Porzsolt F, Wilt TJ.

BJU Int. 2011 Nov;108(10):1556-63. doi: 10.1111/j.1464-410X.2011.10629.x. Epub 2011 Sep 27. Review.

14.

Targeted treatments in advanced renal cell carcinoma: focus on axitinib.

Verzoni E, Grassi P, Testa I, Iacovelli R, Biondani P, Garanzini E, De Braud F, Procopio G.

Pharmgenomics Pers Med. 2014 Mar 27;7:107-16. doi: 10.2147/PGPM.S37098. eCollection 2014. Review.

15.

Renal vein and vena cava involvement does not affect prognosis in patients with renal cell carcinoma.

Ficarra V, Righetti R, D'Amico A, Rubilotta E, Novella G, Malossini G, Mobilio G.

Oncology. 2001;61(1):10-5.

PMID:
11474242
16.

Sorafenib after combination therapy with gemcitabine plus doxorubicine in patients with sarcomatoid renal cell carcinoma: a prospective evaluation.

Staehler M, Haseke N, Roosen A, Stadler T, Bader M, Siebels M, Karl A, Stief CG.

Eur J Med Res. 2010;15:287-91.

17.

Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.

Rini BI, Wilding G, Hudes G, Stadler WM, Kim S, Tarazi J, Rosbrook B, Trask PC, Wood L, Dutcher JP.

J Clin Oncol. 2009 Sep 20;27(27):4462-8. doi: 10.1200/JCO.2008.21.7034. Epub 2009 Aug 3.

18.

Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.

Volpe A, Novara G, Antonelli A, Bertini R, Billia M, Carmignani G, Cunico SC, Longo N, Martignoni G, Minervini A, Mirone V, Simonato A, Terrone C, Zattoni F, Ficarra V; Surveillance and Treatment Update on Renal Neoplasms (SATURN) Project; Leading Urological No-Profit Foundation for Advanced Research (LUNA) Foundation.

BJU Int. 2012 Jul;110(1):76-83. doi: 10.1111/j.1464-410X.2011.10690.x. Epub 2011 Nov 1.

19.

Pazopanib for the treatment of metastatic renal cell carcinoma.

Pick AM, Nystrom KK.

Clin Ther. 2012 Mar;34(3):511-20. doi: 10.1016/j.clinthera.2012.01.014. Epub 2012 Feb 16. Review.

PMID:
22341567
20.

The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus.

Cost NG, Delacroix SE Jr, Sleeper JP, Smith PJ, Youssef RF, Chapin BF, Karam JA, Culp S, Abel EJ, Brugarolas J, Raj GV, Sagalowsky AI, Wood CG, Margulis V.

Eur Urol. 2011 Jun;59(6):912-8. doi: 10.1016/j.eururo.2011.02.032. Epub 2011 Feb 23.

PMID:
21367518
Items per page

Supplemental Content

Write to the Help Desk